trending Market Intelligence /marketintelligence/en/news-insights/trending/ojuokgrfhhmxurg3dv77pa2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Pfizer's Chantix fails to help adolescents quit smoking

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help


Pfizer's Chantix fails to help adolescents quit smoking

Pfizer Inc. said its Chantix smoking-cessation treatment failed to help adolescents kick the habit in a study required by regulators.

The study did not meet its primary endpoint of the four-week continuous abstinence rate at weeks 9 through 12 when compared to placebo.

The phase 4 trial was conducted in nicotine dependent adolescents 12 to 19 years of age. It was not designed to assess the efficacy of the drug.

Chantix, approved as Champix in the EU and other countries, is approved for adults. The New York-based drug giant plans to use the data from the study to seek what is known as a pediatric exclusivity determination.

Such exclusivity, which protects the product from copycat competitors for six months, is offered as an incentive to test medicines in children.